Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice Cover

.blurhash-client-img { display: none !important; }

Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice

Radiology and Oncology

Volume 55 (2021): Issue 4 (December 2021)

By: Marina Mencinger, Dusan Mangaroski and Urska Bokal

Open Access

|May 2021

Authors

Marina Mencinger

mmencinger@onko-i.si

Institute of Oncology Ljubljana, Ljubljana, Slovenia

Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

Dusan Mangaroski

Institute of Oncology Ljubljana, Ljubljana, Slovenia

Urska Bokal

Institute of Oncology Ljubljana, Ljubljana, Slovenia

DOI: https://doi.org/10.2478/raon-2021-0021 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099

Journal RSS Feed

Language: English

Page range: 491 - 498

Submitted on: Sep 27, 2021

Accepted on: Mar 7, 2021

Published on: May 4, 2021

Published by: Association of Radiology and Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

PD-L1 inhibitor,

urothelial cancer,

overall survival,

immune checkpoint inhibitor,

prognostic factors

Related subjects:

Clinical medicine,

Internal medicine,

Haematology, oncology,

© 2021 Marina Mencinger, Dusan Mangaroski, Urska Bokal, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 55 (2021): Issue 4 (December 2021)Next article